Silverarc Capital Management’s Vaxcyte PCVX Stock Holding History

Silverarc Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.43M	Buy	145,000 +19	+0%	+$1.03K	0.88%	36
2026 Q1	$8.42M	Sell	144,981 -3,806	-3%	-$207K	0.86%	30
2025 Q4	$6.87M	Sell	148,787 -165,552	-53%	-$7.4M	0.95%	28
2025 Q3	$11.3M	Buy	314,339 +26,543	+9%	+$879K	1.53%	21
2025 Q2	$9.36M	Buy	+287,796	New	+$9.43M	1.73%	20
2025 Q1	–	Sell	-40,788	Closed	-$3.34M	–	77
2024 Q4	$3.34M	Sell	40,788 -19,712	-33%	-$1.96M	0.73%	38
2024 Q3	$6.91M	Buy	60,500 +58,000	+2,320%	+$5.23M	1.55%	19
2024 Q2	$189K	Buy	+2,500	New	+$170K	0.04%	69
2023 Q1	–	Sell	-83,135	Closed	-$3.99M	–	95
2022 Q4	$3.99M	Buy	+83,135	New	+$3.26M	1.14%	37

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Silverarc Capital Management's PCVX Position: Q2 2026 in Review

Silverarc Capital Management increased its Vaxcyte (PCVX) stake by 0.01% in Q2 2026, buying an estimated $1.03K and bringing the position to 145,000 shares worth $8.43M. The position accounts for 0.88% of the portfolio, ranked #36.

Silverarc Capital Management first reported a position in PCVX in Q4 2022 and has held it in 9 quarters since. The position peaked at $11.3M in Q3 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Silverarc Capital Management held 145,000 shares of Vaxcyte worth $8.43M as of Q2 2026.
Silverarc Capital Management bought 19 Vaxcyte shares in Q2 2026, an estimated $1.03K.
Vaxcyte made up 0.88% of Silverarc Capital Management's portfolio in Q2 2026, its #36 holding.
Silverarc Capital Management first reported a position in Vaxcyte in Q4 2022 and has held it in 9 quarters since.
Silverarc Capital Management's Vaxcyte position peaked at $11.3M in Q3 2025.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.